DE68927438T2 - Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres - Google Patents
Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieresInfo
- Publication number
- DE68927438T2 DE68927438T2 DE68927438T DE68927438T DE68927438T2 DE 68927438 T2 DE68927438 T2 DE 68927438T2 DE 68927438 T DE68927438 T DE 68927438T DE 68927438 T DE68927438 T DE 68927438T DE 68927438 T2 DE68927438 T2 DE 68927438T2
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibodies
- bacteria
- aid
- producing monoclonal
- free animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20625988A | 1988-06-13 | 1988-06-13 | |
PCT/US1989/002545 WO1989012690A1 (en) | 1988-06-13 | 1989-06-12 | Method for the production of monoclonal antibodies utilizing a germfree animal |
Publications (2)
Publication Number | Publication Date |
---|---|
DE68927438D1 DE68927438D1 (de) | 1996-12-12 |
DE68927438T2 true DE68927438T2 (de) | 1997-03-20 |
Family
ID=22765616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE68927438T Expired - Fee Related DE68927438T2 (de) | 1988-06-13 | 1989-06-12 | Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP0413763B1 (de) |
AT (1) | ATE145007T1 (de) |
AU (1) | AU642604B2 (de) |
DE (1) | DE68927438T2 (de) |
SG (1) | SG50681A1 (de) |
WO (1) | WO1989012690A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080883A (en) * | 1990-05-11 | 1992-01-14 | Mallinckrodt, Inc. | 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging |
US5750652A (en) * | 1994-01-21 | 1998-05-12 | Yale University | Deltex proteins |
US5487892A (en) * | 1994-02-24 | 1996-01-30 | American Biogenetic Sciences, Inc. | Method for treating thrombotic disease using a fibrin specific monoclonal antibody |
US5817768A (en) * | 1995-06-07 | 1998-10-06 | The New York Blood Center, Inc. | Monospecific antibodies against a subunit of fibrinogen |
SK287323B6 (sk) | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie |
EP1276500B1 (de) | 2000-03-13 | 2011-06-08 | Cornell Research Foundation, Inc. | Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2 |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US7657379B2 (en) | 2000-07-05 | 2010-02-02 | Microsoft Corporation | Methods and systems for determining the biological function of cell constituents using response profiles |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
MXPA03007493A (es) | 2001-02-20 | 2004-10-15 | Rheogene Holdings Inc | Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado. |
CA2445796C (en) | 2001-02-20 | 2014-09-16 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
EP2374891B1 (de) | 2001-02-20 | 2013-05-08 | Intrexon Corporation | Chimäre Retinoid-X-Rezeptoren und deren Verwendung in einem neuartigen auf Ecdyson-Rezeptoren beruhenden induzierbaren Genexpressionssystem |
JP4994563B2 (ja) | 2001-02-20 | 2012-08-08 | イントレキソン コーポレーション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
JP2005507247A (ja) | 2001-09-26 | 2005-03-17 | レオジーン・ホールディングス,インコーポレーテッド | コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
JP2005532781A (ja) | 2001-09-26 | 2005-11-04 | レオジーン・ホールディングス,インコーポレーテッド | ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
CA2495529C (en) | 2001-10-01 | 2009-05-19 | Mount Sinai School Of Medicine Of New York University | Noonan syndrome gene |
EA008194B1 (ru) | 2002-08-13 | 2007-04-27 | Н-Диа, Инк. | Способы обнаружения амниотической жидкости во влагалищном секрете и устройства для реализации указанных способов |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
WO2005070948A1 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
CN101437539B (zh) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会(有限公司) | 通过干扰cd99l2阻断白细胞迁出和炎症 |
US7666584B2 (en) | 2005-09-01 | 2010-02-23 | Philadelphia Health & Education Coporation | Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer |
US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
US9140692B1 (en) | 2010-01-08 | 2015-09-22 | Glycozym, Inc. | Methods of identifying glycopeptides recognized by disease-associated auto-antibodies |
EP2561355B1 (de) | 2010-04-20 | 2014-06-18 | Cornell University | Verfahren für die diagnose von melanozytenproliferationen |
US9664682B2 (en) | 2012-11-20 | 2017-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Assay to measure midkine or pleiotrophin level for diagnosing a growth |
EP3637105A3 (de) | 2013-01-02 | 2020-07-29 | Qiagen Sciences, LLC | Verfahren zur vorhersage des geburtszeitpunkts bei schwangeren frauen |
WO2014144380A1 (en) | 2013-03-15 | 2014-09-18 | Intrexon Corporation | Boron-containing diacylhydrazines |
JP6567657B2 (ja) | 2014-09-17 | 2019-08-28 | イントレキソン コーポレーション | ホウ素含有ジアシルヒドラジン化合物 |
AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
US10935555B2 (en) | 2016-12-22 | 2021-03-02 | Qiagen Sciences, Llc | Determining candidate for induction of labor |
US10656164B2 (en) | 2016-12-22 | 2020-05-19 | Qiagen Sciences, Llc | Screening asymptomatic pregnant woman for preterm birth |
BR112019022643A2 (pt) * | 2017-05-02 | 2020-05-19 | Nat Cancer Center Japan | conjugado de fármaco-anticorpo anti-fibrina insolúvel clivável por plasmina |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
WO1988001514A1 (en) * | 1986-08-25 | 1988-03-10 | American Biogenetic Sciences, Inc. | Monoclonal antibodies to fibrin |
-
1989
- 1989-06-12 EP EP89906932A patent/EP0413763B1/de not_active Expired - Lifetime
- 1989-06-12 WO PCT/US1989/002545 patent/WO1989012690A1/en active IP Right Grant
- 1989-06-12 SG SG1996008550A patent/SG50681A1/en unknown
- 1989-06-12 DE DE68927438T patent/DE68927438T2/de not_active Expired - Fee Related
- 1989-06-12 AT AT89906932T patent/ATE145007T1/de not_active IP Right Cessation
- 1989-06-12 EP EP95202804A patent/EP0710720A1/de not_active Withdrawn
-
1992
- 1992-08-13 AU AU20976/92A patent/AU642604B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0413763A4 (en) | 1991-09-25 |
WO1989012690A1 (en) | 1989-12-28 |
EP0710720A1 (de) | 1996-05-08 |
AU642604B2 (en) | 1993-10-21 |
SG50681A1 (en) | 1998-07-20 |
ATE145007T1 (de) | 1996-11-15 |
EP0413763B1 (de) | 1996-11-06 |
EP0413763A1 (de) | 1991-02-27 |
DE68927438D1 (de) | 1996-12-12 |
AU2097692A (en) | 1992-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68927438D1 (de) | Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres | |
DE58902737D1 (de) | Verfahren zur herstellung pharmazeutischer mischungen. | |
DE3382190D1 (de) | Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. | |
CA2103059A1 (en) | Method for making humanized antibodies | |
DE69000338D1 (de) | Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. | |
ATA328286A (de) | Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa | |
DE69019120D1 (de) | Künstlicher rasen, florgarn für einen künstlichen rasen sowie verfahren zur herstellung eines derartigen rasens. | |
DE3485054D1 (de) | Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung. | |
DE3877558T2 (de) | Verfahren zur herstellung polybromierter hoeherer alkylbenzole. | |
DE69026695D1 (de) | Verfahren zur herstellung von hochfestem rostfreien bandstahl mit ausgezeichneten federeigenschaften | |
DE69015035D1 (de) | Verfahren zur Herstellung gesinterter Formkörper einer Fe-P-Legierung mit weichmagnetischen Eigenschaften. | |
DE3788900D1 (de) | Verfahren zur Herstellung eines länglichen gesinterten Farmkörpers. | |
DE68904702T2 (de) | Verfahren zur herstellung eines ventilschiebers. | |
DE3880640T2 (de) | Verfahren zur herstellung aliphatischer o-arylurethane. | |
DK0457814T3 (da) | Øget proteinproduktion hos dyr | |
DE3869164D1 (de) | Zahnaerztliche stange mit diamantbeschichtung sowie verfahren zur herstellung. | |
AT399885B (de) | Verfahren zur herstellung von zellinien, die monoklonale antikörper produzieren | |
DE3574601D1 (de) | Antitetanus-antikoerper herstellender human-human-hybridoma und verfahren zu seiner herstellung. | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
DE3881620T2 (de) | Verfahren zur Herstellung eines länglichen Supraleiters. | |
DE58902242D1 (de) | Verfahren zur herstellung von thymol. | |
DE69101601D1 (de) | Verfahren zur Herstellung eines Milchprotein-Isolates. | |
DE3886871D1 (de) | Verfahren zur Herstellung eines Feldeffekttransistors mit Übergangsgatter. | |
ATE184877T1 (de) | Übergangsmetallkomplex zur verwendung als diagnostisches oder therapeutisches arzneimittel | |
ATE144286T1 (de) | Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |